Payment overview · 2025
General Payments
$67.28
4 reported records · 4 companies
Healthcare provider profile · identity verified
Patrick Malone, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MEMPHIS, TN · NPI 1194710160
Verified facts
What the public records show
CMS Open Payments records show Patrick Malone, M.D. received $67.28 in general payments during 2025 across 4 reported records.
Dynavax Technologies Corporation accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $21.50 | 32.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.51 | 26.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.22 | 21.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.05 | 20.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $67.28 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 718 | 213 |
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 139 |
| Omeprazole | Omeprazole | 277 | 76 |
| Metformin Hcl | Metformin Hcl | 228 | 71 |
| Lisinopril | Lisinopril | 200 | 64 |
| Losartan Potassium | Losartan Potassium | 189 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 55 |
| Furosemide | Furosemide | 173 | 55 |
| Carvedilol | Carvedilol | 160 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 40 |
| Gabapentin | Gabapentin | 112 | 37 |
| Jardiance | Empagliflozin | 112 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 37 |
| Meloxicam | Meloxicam | 102 | 44 |
| Potassium Chloride | Potassium Chloride | 101 | 28 |
| Simvastatin | Simvastatin | 100 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 25 |
| Ibuprofen | Ibuprofen | 81 | 29 |
| Benazepril Hcl | Benazepril Hcl | 76 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 28 |
| Baclofen | Baclofen | 66 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 22 |
| Allopurinol | Allopurinol | 65 | 24 |
| Glimepiride | Glimepiride | 65 | 21 |
| Clonidine Hcl | Clonidine Hcl | 61 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 18 |
| Atenolol | Atenolol | 51 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 51 | 14 |
| Spironolactone | Spironolactone | 50 | 16 |
| Eliquis | Apixaban | 49 | 15 |
| Metformin Hcl Er | Metformin Hcl | 43 | 12 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 18 |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 15 |
| Clotrimazole | Clotrimazole | 32 | 17 |
| Glipizide | Glipizide | 31 | 11 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Prednisone | Prednisone | 23 | 20 |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | 13 |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | 11 |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Trueplus Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $67.28 · 4 records | Dynavax Technologies Corporation | Dexcom G6 Transmitter, Heplisav-B, MOUNJARO, The Cologuard Plus Collection Kit, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error